Alzheimer disease biomarkers are associated with decline in subjective memory, attention, and spatial navigation ability in clinically normal adults.

IF 2.6 4区心理学 Q2 CLINICAL NEUROLOGY Journal of the International Neuropsychological Society Pub Date : 2024-05-01 Epub Date: 2023-11-28 DOI:10.1017/S135561772300070X

Taylor F Levine, Steven J Dessenberger, Samantha L Allison, Denise Head

{"title":"Alzheimer disease biomarkers are associated with decline in subjective memory, attention, and spatial navigation ability in clinically normal adults.","authors":"Taylor F Levine, Steven J Dessenberger, Samantha L Allison, Denise Head","doi":"10.1017/S135561772300070X","DOIUrl":null,"url":null,"abstract":"Objective: Subtle changes in memory, attention, and spatial navigation abilities have been associated with preclinical Alzheimer disease (AD). The current study examined whether baseline AD biomarkers are associated with self- and informant-reported decline in memory, attention, and spatial navigation.Method: Clinically normal (Clinical Dementia Rating Scale (CDR®) = 0) adults aged 56-93 (N = 320) and their informants completed the memory, divided attention, and visuospatial abilities (which assesses spatial navigation) subsections of the Everyday Cognition Scale (ECog) annually for an average of 4 years. Biomarker data was collected within (±) 2 years of baseline (i.e., cerebrospinal fluid (CSF) p-tau181/Aβ42 ratio and hippocampal volume). Clinical progression was defined as CDR > 0 at time of final available ECog.Results: Self- and informant-reported memory, attention, and spatial navigation significantly declined over time (ps < .001). Baseline AD biomarkers were significantly associated with self- and informant-reported decline in cognitive ability (ps < .030), with the exception of p-tau181/Aβ42 ratio and self-reported attention (p = .364). Clinical progression did not significantly moderate the relationship between AD biomarkers and decline in self- or informant-reported cognitive ability (ps > .062). Post-hoc analyses indicated that biomarker burden was also associated with self- and informant-reported decline in total ECog (ps < .002), and again clinical progression did not significantly moderate these relationships (ps > .299).Conclusions: AD biomarkers at baseline may indicate risk of decline in self- and informant-reported change in memory, attention, and spatial navigation ability. As such, subjectively reported decline in these domains may have clinical utility in tracking the subtle cognitive changes associated with the earliest stages of AD.","PeriodicalId":49995,"journal":{"name":"Journal of the International Neuropsychological Society","volume":" ","pages":"313-327"},"PeriodicalIF":2.6000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the International Neuropsychological Society","FirstCategoryId":"102","ListUrlMain":"https://doi.org/10.1017/S135561772300070X","RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Subtle changes in memory, attention, and spatial navigation abilities have been associated with preclinical Alzheimer disease (AD). The current study examined whether baseline AD biomarkers are associated with self- and informant-reported decline in memory, attention, and spatial navigation.

Method: Clinically normal (Clinical Dementia Rating Scale (CDR®) = 0) adults aged 56-93 (N = 320) and their informants completed the memory, divided attention, and visuospatial abilities (which assesses spatial navigation) subsections of the Everyday Cognition Scale (ECog) annually for an average of 4 years. Biomarker data was collected within (±) 2 years of baseline (i.e., cerebrospinal fluid (CSF) p-tau₁₈₁/Aβ₄₂ ratio and hippocampal volume). Clinical progression was defined as CDR > 0 at time of final available ECog.

Results: Self- and informant-reported memory, attention, and spatial navigation significantly declined over time (ps < .001). Baseline AD biomarkers were significantly associated with self- and informant-reported decline in cognitive ability (ps < .030), with the exception of p-tau₁₈₁/Aβ₄₂ ratio and self-reported attention (p = .364). Clinical progression did not significantly moderate the relationship between AD biomarkers and decline in self- or informant-reported cognitive ability (ps > .062). Post-hoc analyses indicated that biomarker burden was also associated with self- and informant-reported decline in total ECog (ps < .002), and again clinical progression did not significantly moderate these relationships (ps > .299).

Conclusions: AD biomarkers at baseline may indicate risk of decline in self- and informant-reported change in memory, attention, and spatial navigation ability. As such, subjectively reported decline in these domains may have clinical utility in tracking the subtle cognitive changes associated with the earliest stages of AD.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

阿尔茨海默病生物标志物与临床正常成人主观记忆、注意力和空间导航能力下降有关。

目的:记忆、注意力和空间导航能力的细微变化与临床前阿尔茨海默病(AD)有关。目前的研究调查了基线AD生物标志物是否与自我报告的记忆、注意力和空间导航能力下降有关。方法:临床正常(临床痴呆评定量表(CDR®)= 0)56-93岁的成年人(N = 320)及其被调查者平均每年完成日常认知量表(ECog)的记忆、分散注意力和视觉空间能力(评估空间导航)部分，平均持续4年。在基线(±)2年内收集生物标志物数据(即脑脊液(CSF) p-tau181/ a - β42比值和海马体积)。临床进展定义为最终可用心电图时CDR > 0。结果:自我和被调查者报告的记忆、注意力和空间导航能力随着时间的推移显著下降(ps < 0.001)。基线AD生物标志物与自我报告的认知能力下降显著相关(p < 0.030)， p-tau181/ a - β42比值和自我报告的注意力除外(p = .364)。临床进展没有显著调节AD生物标志物与自我或线人报告的认知能力下降之间的关系(ps > 0.062)。事后分析表明，生物标志物负担也与自我报告的总ECog下降相关(ps < 0.002)，临床进展再次没有显著缓解这种关系(ps > 0.299)。结论:阿尔茨海默病的生物标志物基线可能表明自我和线人报告的记忆、注意力和空间导航能力变化的下降风险。因此，主观报告这些领域的下降可能在追踪与阿尔茨海默病早期相关的细微认知变化方面具有临床应用价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of the International Neuropsychological Society 医学-精神病学

CiteScore

5.40

自引率

3.80%

发文量

185

审稿时长

4-8 weeks

期刊介绍： The Journal of the International Neuropsychological Society is the official journal of the International Neuropsychological Society, an organization of over 4,500 international members from a variety of disciplines. The Journal of the International Neuropsychological Society welcomes original, creative, high quality research papers covering all areas of neuropsychology. The focus of articles may be primarily experimental, applied, or clinical. Contributions will broadly reflect the interest of all areas of neuropsychology, including but not limited to: development of cognitive processes, brain-behavior relationships, adult and pediatric neuropsychology, neurobehavioral syndromes (such as aphasia or apraxia), and the interfaces of neuropsychology with related areas such as behavioral neurology, neuropsychiatry, genetics, and cognitive neuroscience. Papers that utilize behavioral, neuroimaging, and electrophysiological measures are appropriate. To assure maximum flexibility and to promote diverse mechanisms of scholarly communication, the following formats are available in addition to a Regular Research Article: Brief Communication is a shorter research article; Rapid Communication is intended for "fast breaking" new work that does not yet justify a full length article and is placed on a fast review track; Case Report is a theoretically important and unique case study; Critical Review and Short Review are thoughtful considerations of topics of importance to neuropsychology and include meta-analyses; Dialogue provides a forum for publishing two distinct positions on controversial issues in a point-counterpoint format; Special Issue and Special Section consist of several articles linked thematically; Letter to the Editor responds to recent articles published in the Journal of the International Neuropsychological Society; and Book Review, which is considered but is no longer solicited.